Midatech Pharma Plc Prix/Valeur
Quel est le Prix/Valeur de Midatech Pharma Plc?
Le Prix/Valeur de Midatech Pharma Plc est 0.42
Quelle est la définition de Prix/Valeur?
Le ratio cours / valeur comptable représente le rapport entre la valeur des actions d'une entreprise et la valeur comptable par action.
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Prix/Valeur des entreprises dans Health Care secteur sur LSE par rapport à Midatech Pharma Plc
Que fait Midatech Pharma Plc?
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Entreprises avec prix/valeur similaire à Midatech Pharma Plc
- Mega Uranium a Prix/Valeur de 0.42
- Treasury Metals a Prix/Valeur de 0.42
- Dominate a Prix/Valeur de 0.42
- Enviroleach Technologies a Prix/Valeur de 0.42
- Strategic Minerals Plc a Prix/Valeur de 0.42
- Galleon Gold a Prix/Valeur de 0.42
- Midatech Pharma Plc a Prix/Valeur de 0.42
- Beaver () a Prix/Valeur de 0.42
- Associated International Hotels a Prix/Valeur de 0.42
- Lustrum Minerals a Prix/Valeur de 0.42
- Vita a Prix/Valeur de 0.42
- INPEX a Prix/Valeur de 0.42
- Huan Yue Interactive a Prix/Valeur de 0.42